Gene therapy targeting hematopoietic cells: Better not leave it to chance

Acta Haematologica

Volumn 110, Issue 2-3, 2003, Pages 107-109

  Baum, Christopher ^a,b   Von Kalle, Christof ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Gene therapy; Mutagenesis; Retroviral vector; Transformation

Indexed keywords

RECOMBINANT DNA;

CELL CLONE; CHROMOSOME; DNA REPAIR; GENE TARGETING; GENE TECHNOLOGY; GENE THERAPY; GENETIC DISORDER; GENETIC ENGINEERING; HEMATOPOIESIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; TRANSGENE; TRANSGENICS;

ANIMALS; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 0242331186     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072459     Document Type: Review

References (9)

1. Rideout WM 3rd, Hochedlinger K, Kyba M, Daley GQ, Jaenisch R: Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell 2002;109:17-27.
2. Humpherys D, Eggan K, Akutsu H, Friedman A, Hochedlinger K, Yanagimachi R, Lander ES, Golub TR, Jaenisch R: Abnormal gene expression in cloned mice derived from embryonic stem cell and cumulus cell nuclei. Proc Natl Acad Sci USA 2002;99:12889-12894.
3. Baum C, Düllmann J, Li Z, Fehse B, Meyer J, Williams DA, Von Kalle C: Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003;101:2099-2114.
4. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, Fischer A, Davies EG, Kuis W, Leiva L, Cavazzana-Calvo M: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002;346: 1185-1193.
5. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, Carlucci F, Marinello E, Cattaneo F, Vai S, Servida P, Miniero R, Roncarolo MG, Bordignon C: Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002;296:2410-2413.
6. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348:255-256.
7. Li Z, Düllmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J, Forster M, Stocking C, Wahlers A, Frank O, Ostertag W, Kuhlcke K, Eckert HG, Fehse B, Baum C: Murine leukemia induced by retroviral gene marking. Science 2002;296:497.
8. Schmidt M, Hoffmann G, Wissler M, Lemke N, Mussig A, Glimm H, Williams DA, Ragg S, Hesemann CU, von Kalle C: Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples. Hum Gene Ther 2001;12:743-749.
9. Check E: Regulators split on gene therapy as patient shows signs of cancer. Nature 2002; 419:545-546.